Nat Med:同期两项糖尿病重要成果

2015-04-08 王英 生物通

最近,加拿大多伦多综合医院研究所的研究人员发现,二甲双胍(最广泛使用的2型糖尿病治疗药物)和白藜芦醇——在红葡萄酒中发现的一种化合物,可触发小肠中的新信号转导通路,从而降低血糖。该研究结果以两篇论文的形式发布在四月六日同期出版的《Nature Medicine》杂志。该研究小组由Tony Lam博士和他的同事Frank Duca带领,包括研究生Clemence Cote和Brittany Rasm

最近,加拿大多伦多综合医院研究所的研究人员发现,二甲双胍(最广泛使用的2型糖尿病治疗药物)和白藜芦醇——在红葡萄酒中发现的一种化合物,可触发小肠中的新信号转导通路,从而降低血糖。该研究结果以两篇论文的形式发布在四月六日同期出版的 Nature Medicine 杂志。

该研究小组由Tony Lam博士和他的同事Frank Duca带领,包括研究生Clemence Cote和Brittany Rasmussen。他们用肥胖和糖尿病大鼠模型,发现二甲双胍和白藜芦醇可分别激活小肠中被称为AMPK和Sirtuin 1的分子,并触发一种涉及肠道、脑和肝脏的神经元网络,降低血糖。

本研究中所用的一种化合物是2型糖尿病患者的常用药物二甲双胍,另外一种化合物是白藜芦醇——存在于红葡萄酒、葡萄、花生、蓝莓的一种化合物。虽然在细胞培养和动物中进行的研究表明,白藜芦醇已经显示出抑制癌细胞、抗感染能力和降低血糖或血糖水平的作用,但是该化合物对人体的影响尚不清楚。

这两篇论文的共同第一作者Frank Duca博士指出:“几乎80%的2型糖尿病患者都超重或肥胖问题,因此他们更难控制自己的血糖水平。我们的工作表明,这两种抗糖尿病药物可直接靶定肠道——以前在糖尿病治疗中不受重视的一个器官,来降低血糖水平,即使在肥胖或糖尿病大鼠中。这方面的知识将帮助我们开发更有效、有针对性的药物,具有更少副作用。”

Lam博士指出:“我们已经知道,大脑和肝脏调节血糖水平,但问题是,你如何从治疗上靶定这两个器官,而不产生副作用?我们通过表明小肠中的分子可能是最初靶标,为这个问题找到一种解决办法。如果能开发出新的药物刺激肠道内这些传感分子,我们可能就会有效地减缓身体的糖生产,从而降低糖尿病患者的血糖水平。”

Lam博士强调,这将需要数年的实验工作,以确定是否目前的结果与人类相关。
 
超过二百万的加拿大人患有糖尿病。目前,糖尿病患者通过饮食、锻炼、抗糖尿病药或注射胰岛素(通常是一天几次)来降低血糖,必须定期监测血糖水平。高血糖可引起眼睛、神经和肾脏的伤害,并增加心脏病中风、失明、勃起功能障碍、足部问题和截肢的风险。世界各地的许多实验室都在寻找可替代的有效方法来降低血糖水平,因为高血糖会导致严重的并发症。这两篇论文目前的研究结果意味着,用小分子化合物靶定肠道,可能是降低血糖水平、减少糖尿病并发症发生的替代策。

原始出处:

1.Frank A Duca, Clémence D Côté,Brittany A Rasmussen,et al.Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats.Nature Medicine (2015), Published online 06 April 2015;doi:10.1038/nm.3787

2.Clémence D Côté,Brittany A Rasmussen, Frank A Duca,et al.Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.Nature Medicine (2015) ,Published online 06 April 2015;doi:10.1038/nm.3821

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-07-25 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-12-12 mnda
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-06-26 zywlvao
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-07-28 shuaijing1986

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-06-11 ljjj1053

    好好学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-04-11 x35042875

    AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-04-09 lecoo

    跟上

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-04-08 szzyy

    有点意思,继续追踪

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1880578, encodeId=47ab18805e87e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 25 10:50:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814831, encodeId=02eb181483167, content=<a href='/topic/show?id=5bc79606689' target=_blank style='color:#2F92EE;'>#重要成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96066, encryptionId=5bc79606689, topicName=重要成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Sat Dec 12 18:50:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709111, encodeId=3a4c1e09111bb, content=<a href='/topic/show?id=cd013896021' target=_blank style='color:#2F92EE;'>#同期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38960, encryptionId=cd013896021, topicName=同期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dd731593408, createdName=zywlvao, createdTime=Fri Jun 26 03:50:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33622, encodeId=cc8b3362291, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Jul 28 06:39:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27083, encodeId=16052e083fc, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:39:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20311, encodeId=960d203117a, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:37:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606467, encodeId=1c72160646eee, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 10 07:50:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20016, encodeId=202a200167a, content=跟上, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Thu Apr 09 18:27:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19973, encodeId=138c199e35e, content=有点意思,继续追踪, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=szzyy, createdTime=Wed Apr 08 20:24:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19966, encodeId=6b5b1996603, content=实用性并不强, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.234.**, createdTime=Wed Apr 08 19:45:00 CST 2015, time=2015-04-08, status=1, ipAttribution=)]
    2015-04-08 175.0.234.**

    实用性并不强

    0

相关资讯

JAMA:积极降压治疗可降2型糖尿病患者死亡率

乔治全球健康研究所发表的一项系统回顾和荟萃分析表明,在2型糖尿病患者中,降压治疗与死亡率降低相关,在基线血压值≥140 mmHg的患者中,降压降低其他临床指标相对风险的作用更明显。研究结果支持对上述患者进行药物降压治疗。文章2月10日在线发表于《美国医学会杂志》(简称JAMA)。 降压治疗广泛运用于降低糖尿病患者心血管病风险,本文旨在探讨糖尿病患者降压治疗与心血管病间的关系 。研

Lancet:阿格列汀不增加2型糖尿病心衰风险(EXAMINE 试验)

先前有一项EXAMINE研究证明DPP-4抑制剂阿格列汀与安慰剂相比,在增加T2DM主要心血管事件风险中呈非劣性。而另一项报道称使用DPP-4抑制剂可能增加住院患者心衰风险,令人担忧。因此,近来有研究进行另一项EXAMINE评估阿格列汀对入院患者发生心衰的影响。 试验中,研究者将已接受糖尿病标准化和心血管疾病预防治疗的2型糖尿病合并ACS患者,随机分为阿格列汀或安慰剂治疗组。 预先设定的评价终

JAMA:家族性高胆固醇血症与2型糖尿病的患病率之间的关联

家族性高胆固醇血症的特征在于外周组织中胆甾醇受损,包括肝和胰腺的受损摄取。与此相反,他汀类药物增加了细胞内胆固醇的吸收,并与2型糖尿病的风险增加有关。我们推测这种跨膜胆固醇运输与2型糖尿病的发展有关。 目的 评价2型糖尿病的患病率和家族性高胆固醇之间的关联。 设计 地点和参与者 1994至2014年间荷兰全国筛查方案所有接受族性高胆固醇血症DNA测试的人(n =63320)。 基于文献或实验

Diabetologia:妊娠期糖尿病孕妈妈要小心!

妊娠期间的糖尿病有两种情况,一种为妊娠前已确诊糖尿病,称“糖尿病合并妊娠”;另一种为妊娠前糖代谢正常或有潜在糖耐量减退、妊娠期才出现或确诊的糖尿病,称为“妊娠期糖尿病(GDM)”。妊娠期糖尿病(GDM)孕妇糖代谢多数于产后能恢复正常,但将来患2型糖尿病机会增加。

才子佳人!GSK携手冷泉港向肥胖和二型糖尿病发起冲锋

最近,美国生物医药研究重镇冷泉港实验室宣布将与英国生物医药巨头葛兰素史克公司建立长期合作。双方将在肥胖和二型糖尿病新疗法的研究开发方面进行合作研究。 协议规定,冷泉港实验室和葛兰素史克公司的研究人员将围绕PTP1B这种蛋白酪氨酸磷酸化酶进行研究。PTP1B被认为在机体产生胰岛素抵抗和瘦素抵抗中起到重要作用,这些早已成为困扰肥胖症和糖尿病治疗领域多时的难题。 数据显示,2011年全世界共

JCI:胖子的免疫T细胞们

近年来,肥胖和2型糖尿病发病率呈上升趋势。在这些人群的脂肪组织中,免疫细胞的累计引起了慢性炎症。另外,肠道中的微生物群也有所改变。通过节食或者胃旁路手术减轻体重,可以改善2型糖尿病症状,改变肠道菌群。 近日,Agnès Lehuen博士和他的同事们在国际临床研究杂志《Journal of Clinical Investigation》上,在线发表了一项新的研究成果。研究人员发现,一群名为黏膜相关